Predictive Role of Acute Phase Reactants in the Response to Therapy in Patients with Chronic Hepatitis C Virus Infection
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Biochemical parameters and acute-phase proteins (APPs) may provide complementary data in patients with chronic hepatitis C (CHC). We aimed to evaluate the predictive role of APPs in the response to antiviral therapy. Methods: Forty-five patients underwent antiviral therapy. Serum ferritin, C-reactive protein (CRP), transferrin, albumin, alpha-1 acid glycoprotein (A1AG), and alpha-2 macroglobulin (A2MG) levels were examined at the initial evaluation and at the 4th, 12th, and 48th weeks. HCV RNA levels were examined at the initial evaluation and at the 12th and 48th weeks. Results: Ferritin, transferrin, A1AG, and A2MG levels were significantly higher in the patient group (p<0.05). CRP, ferritin, A1AG, and A2MG levels were significantly increased from baseline to the 4th week (p<0.05). The responders and nonresponders to antiviral therapy had insignificantly but remarkably different levels of CRP, ferritin, transferrin, A1AG, A2MG, and alanine aminotransferase (ALT) both at the initial evaluation and at the 12th week. Conclusions: Variations in ferritin, A1AG, A2MG, albumin, CRP, and transferrin levels are not alternatives to virological and biochemical parameters for predicting an early response to therapy in patients with CHC. However, the investigation of ALT levels and hepatitis C virus RNA in combination with acute-phase reactants may provide supplementary data for evaluating responses to antiviral therapy.
Abstract
Background/Aims: Biochemical parameters and acute-phase proteins (APPs) may provide complementary data in patients with chronic hepatitis C (CHC). We aimed to evaluate the predictive role of APPs in the response to antiviral therapy. Methods: Forty-five patients underwent antiviral therapy. Serum ferritin, C-reactive protein (CRP), transferrin, albumin, alpha-1 acid glycoprotein (A1AG), and alpha-2 macroglobulin (A2MG) levels were examined at the initial evaluation and at the 4th, 12th, and 48th weeks. HCV RNA levels were examined at the initial evaluation and at the 12th and 48th weeks. Results: Ferritin, transferrin, A1AG, and A2MG levels were significantly higher in the patient group (p<0.05). CRP, ferritin, A1AG, and A2MG levels were significantly increased from baseline to the 4th week (p<0.05). The responders and nonresponders to antiviral therapy had insignificantly but remarkably different levels of CRP, ferritin, transferrin, A1AG, A2MG, and alanine aminotransferase (ALT) both at the initial evaluation and at the 12th week. Conclusions: Variations in ferritin, A1AG, A2MG, albumin, CRP, and transferrin levels are not alternatives to virological and biochemical parameters for predicting an early response to therapy in patients with CHC. However, the investigation of ALT levels and hepatitis C virus RNA in combination with acute-phase reactants may provide supplementary data for evaluating responses to antiviral therapy.
참고문헌 (42)
- Kim WR, "The burden of hepatitis C in the United States", Hepatology, 36(5 Suppl), pp.S30~S34 (2002)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Poynard T, "Viral hepatitis C", Lancet, 362, pp.2095~2100 (2003)
- Radziewicz H, "Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling", J Immunol, 184, pp.2410~2422 (2010)
- Fontana RJ, "Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial", Hepatology, 31, pp.730~736 (2000)
- Smith BC, "Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C", Hepatology, 27, pp.1695~1699 (1998)
- Valenti L, "Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis", Haematologica, 92, pp.1037~1042 (2007)
- Naveau S, "Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest", Dig Dis Sci, 39, pp.2426~2432 (1994)
- Tiggelman AM, "Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas", Hepatology, 23, pp.1260~1267 (1996)
- 장재영, "Chronic Hepatitis C", Gut and Liver, 5(2), pp.117~132 (2011), 거트앤리버 발행위원회
- Lindsay KL, "Introduction to therapy of hepatitis C", Hepatology, 36(5 Suppl), pp.S114~S120 (2002)
- Jonsson JR, "Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C", Hepatology, 48, pp.80~87 (2008)
- Ait-Goughoulte M, "Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response", Hepatology, 51, pp.1505~1513 (2010)
- Akkus I, "Clinical biochemistrical laboratory handbook", pp.15~55 (1997), Oz Egitim Basım Yayın Dagıtım Ltd. Sti.
- Tsui JI, "Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study", J Card Fail, 15, pp.451~456 (2009)
- Bourliere M, "Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients", Aliment Pharmacol Ther, 28, pp.458~467 (2008)
- Shima M, "Comparative study of C-reactive protein in chronic hepatitis B and hepatitis C", Tohoku J Exp Med, 178, pp.287~297 (1996)
- Atono Y, "Kinetics of C-reactive protein in acute viral hepatitis", Gastroenterol Jpn, 24, pp.655~662 (1989)
- Huang CF, "Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients", Hepatol I, 4, pp.621~627 (2010)
- Biro L, "Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b", Immunol Lett, 72, pp.69~74 (2000)
- Ono K, "Biological responses to administered interferon in alcoholics", Alcohol Clin Exp Res, 20, pp.1560~1563 (1996)
- Lapinski TW, "Activation of acute phase proteins in patients with chronic hepatitis C treated with interferon-alpha 2a", Pol Merkur Lekarski, 10, pp.138~142 (2001)
- Bolewska B, "Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment", Pol Merkur Lekarski, 18, pp.552~555 (2005)
- Stam TC, "Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b", Eur J Clin Invest, (32 Suppl 1), pp.79~83 (2002)
- Mozer-Lisewska I, "Alterations of soluble transferrin receptor level in children with chronic hepatitis C during treatment with recombinant interferon-alpha and ribavirin", Hepatol Res, 33, pp.19~23 (2005)
- Martin-Vivaldi R, "Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism", Rev Esp Enferm Dig, 89, pp.523~530 (1997)
- Casaril M, "Role of iron load on fibrogenesis in chronic hepatitis C", Hepatogastroenterology, 47, pp.220~225 (2000)
- Bayraktar Y, "The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B", Hepatogastroenterology, 45, pp.2322~2327 (1998)
- Ioannou GN, "Racial differences in the relationship between hepatitis C infection and iron stores", Hepatology, 37, pp.795~801 (2003)
- Hofer H, "Hepatic iron concentration does not predict response to standard and pegylated-IFN", ribavirin therapy in patients with chronic hepatitis C, 2004, pp.40, 1018~1022
- Metwally MA, "Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection", Am J Gastroenterol, 99, pp.286~291 (2004)
- Arber N, "Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection", Dig Dis Sci, 40, pp.2431~2433 (1995)
- Kalabay L, "Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b", Int Immunol, 16, pp.51~54 (2004)
- Weiss G, "Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection", J Infect Dis, 180, pp.1452~1458 (1999)
- Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study", Lancet, 357, pp.1069~1075 (2001)
- Patel K, "Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients", J Hepatol, 41, pp.935~942 (2004)
- Feher J, "Serum immunoglobulin and glycoprotein concentration and mesenchymal reaction in chronic hepatitis and liver cirrhosis", Morphol Igazsagugyi Orv Sz, 17, pp.180~186 (1977)
- Poynard T, "Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial", J Viral Hepat, 9, pp.128~133 (2002)
- Ho AS, "Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI", J Biomed Sci, 17, pp.58~ (2010)
- Anderson S, "Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection", Dig Dis Sci, 46, pp.1393~1398 (2001)
- Luo JC, "Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C", Hepatogastroenterology, 49, pp.478~481 (2002)
- Volchkova EV, "Changes in the levels of acute phase proteins in viral hepatitis", Ter Arkh, 72, pp.18~21 (2000)